AbbVie Inc. Files 8-K Report

TL;DR

AbbVie filed an 8-K on 9/11/25 for financial disclosures.

AI Summary

On September 11, 2025, AbbVie Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure. No specific material events or financial figures beyond the filing date and company information were detailed in the provided text.

Why It Matters

This filing indicates AbbVie Inc. is providing updated financial information and disclosures to the SEC, which is standard practice for public companies.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

• AbbVie Inc. (company) — Filer of the 8-K report
• September 11, 2025 (date) — Date of the earliest event reported

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 Par Value ABBV New York Stock Excha

Filing Documents

• tm2525781d1_8k.htm (8-K) — 38KB
• 0001104659-25-089245.txt ( ) — 274KB
• abbv-20250911.xsd (EX-101.SCH) — 4KB
• abbv-20250911_def.xml (EX-101.DEF) — 29KB
• abbv-20250911_lab.xml (EX-101.LAB) — 39KB
• abbv-20250911_pre.xml (EX-101.PRE) — 27KB
• tm2525781d1_8k_htm.xml (XML) — 10KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On September 11, 2025, AbbVie announced that it has settled litigation with all generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, which AbbVie markets as RINVOQ. Given the settlement and license agreements, which are subject to standard acceleration provisions, assuming pediatric exclusivity is granted, no generic entry for any upadacitinib tablets is expected prior to April 2037 in the United States. Some statements in this filing are, or may be considered, forward-looking "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, adverse litigation or government action, changes to laws and regulations applicable to our industry, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: September 11, 2025 By: /s/ Perry C. Siatis Perry C. Siatis Executive Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR